Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Age ≥ 18 years~* Complete and adequate resection of Stage III melanoma with histologically confirmed melanoma metastatic to lymph node~* Disease-free~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~* Randomization within 12 weeks of surgery~Exclusion Criteria:~* Prior therapy for melanoma except surgery~* Auto-immune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).